Meeting
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
Authors
Thomas Powles
Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Thomas Powles , Elizabeth R. Plimack , Viktor Stus , Rustem Airatovich Gafanov , Robert E. Hawkins , Dmitry Nosov , Frederic Pouliot , Boris Yakovlevich Alekseev , Denis Soulieres , Bohuslav Melichar , Ihor Vynnychenko , Anna Kryzhanivska , Igor Bondarenko , Sergio Jobim Azevedo , Delphine Borchiellini , Qiong Shou , Rodolfo F. Perini , Mei Chen , Michael B. Atkins , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02853331
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 543)
DOI
10.1200/JCO.2019.37.7_suppl.543
Abstract #
543
Poster Bd #
D4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
First Author: Salma K. Jabbour
Poster
2020 Genitourinary Cancers Symposium
Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011.
First Author: Yohann Loriot
Poster
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC).
First Author: Brian I. Rini
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin